TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04322682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Study: NCT01471483

Intervention type: BEHAVIORAL
Intervention: geriatric assessment and telephone call from nurse
Description: The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.

Intervention type: OTHER
Intervention: geriatric assessment and no call from nurse
Description: The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
Study: NCT01221987

Intervention type: PROCEDURE
Intervention: Cervical sampling
Description: Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types

Intervention type: PROCEDURE
Intervention: Cervical sampling
Description: Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion
Study: NCT02196649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Clip
Study: NCT05283317

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
Study: NCT01930110

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40-minute interval exercise
Description: Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40-minute interval exercise
Description: Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
Study: NCT01641250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Multiple escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Multiple escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
Study: NCT01270126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transorbital alternating current stimulation
Description: Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
Study: NCT02158676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Fructooligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT00990990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 100 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 100 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 300 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 300 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 600 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 1200 mg QD for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: to match 1200 mg QD for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 300 mg QD for 4 days (open label)
Study: NCT03628209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
Study: NCT03926078

Intervention type: OTHER
Group type: OTHER
Intervention: 3D optical surface image
Description: 3D optical surface images will be acquired and used to calculate the EHI

Intervention type: OTHER
Group type: OTHER
Intervention: 3D optical surface image
Description: 3D optical surface images will be acquired and used to calculate the EHI
Study: NCT03628209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Treatment Surgery
Description: Resection surgery at end of Cycle 1 treatment, day 28-35.
Study: NCT03926078

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest radiography
Description: Chest radiographies will be acquired and used to calculated the HI and EHI

Intervention type: RADIATION
Group type: OTHER
Intervention: CT scan
Description: CT scans will be acquired and used to calculate the HI and EHI
Study: NCT04098874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Extended Release Oral Tablet
Description: 12 weeks postpartum of blinded study medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 12 weeks postpartum of blinded placebo
Study: NCT03985592

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Intervention description provided in elaboration on arms of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Intervention description provided in elaboration on arms of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Intervention description provided in elaboration on arms of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Intervention description provided in elaboration on arms of the study.
Study: NCT02251587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Management Program
Description: Standard Diet program based on diet and exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensible Weigh Program
Description: Weight loss program designed for low income women.
Study: NCT01977326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: basic counselling by lay-health workers
Description: 6 sessions of manual based counselling by trained lay health workers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 3 monthly phone calls by trained lay health workers (without counselling)
Study: NCT03198299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEI BIN insoles
Description: wearing insoles for 12 weeks
Study: NCT02405611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral
Description: The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
Study: NCT04288635

Intervention type: BIOLOGICAL
Intervention: Whole blood samples
Description: Whole blood samples at admission, from day one to three after admission
Study: NCT02515760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration from the iliac crest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration from the iliac crest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illinois bone marrow aspiration neddle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illinois bone marrow aspiration neddle
Study: NCT02738866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
Study: NCT03941080

Intervention type: DIAGNOSTIC_TEST
Intervention: fecal sample
Description: patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: 4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
Study: NCT03444428

Intervention type: OTHER
Intervention: Non Invasive Ventilation
Description: Assessments for those participants who are being set up onto NIV

Intervention type: OTHER
Intervention: Without Non Invasive Ventilation
Description: Assessments for those participants who are not being set up onto NIV
Study: NCT03642964

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTC-501
Description: pramipexole IR, given with ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTC-501
Description: pramipexole IR, given with ondansetron
Study: NCT01809301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIA-662
Study: NCT02273063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
Study: NCT00656292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 40 mg po/nasogastric tube (NG) every day for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 pill po/NG every day x 6 days
Study: NCT01677572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
Description: Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Study: NCT02118220

Intervention type: OTHER
Group type: OTHER
Intervention: Concussion Questionnaire
Study: NCT03584451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation sport
Description: rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
Study: NCT04464928

Intervention type: OTHER
Intervention: Facebook Advertisements
Description: Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.

Intervention type: OTHER
Intervention: Google Advertisements
Description: Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
Study: NCT04617639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Observation group
Description: Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
Study: NCT02430194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor
Study: NCT00776984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
Study: NCT00728832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Description: DepoDur with on demand boluses of IV fentanyl PCA
Study: NCT01856647

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy (fat biopsy)
Description: An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy (fat biopsy)
Description: An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy (fat biopsy)
Description: An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy (fat biopsy)
Description: An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
Study: NCT01209936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D2O
Description: All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
Study: NCT01677572

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Study: NCT01779128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-PET
Study: NCT00998647

Intervention type: DEVICE
Intervention: modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus
Description: usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids

Intervention type: DEVICE
Intervention: modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus
Description: usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
Study: NCT01519219

Intervention type: RADIATION
Intervention: Hepatic Irradiation
Description: Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
Study: NCT02589626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes
Study: NCT02946372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal limiting membrane transplantation (ILMT)
Description: internal limiting membrane autologous transplantation (ILMT)
Study: NCT03951883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased Egg Consumption
Description: Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical diet
Description: Subjects will be instructed to maintain their current dietary patterns.
Study: NCT00885664

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada (tenofovir/emtricitabine)
Description: Tenofovir/emtricitabine fixed dose combination once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada (tenofovir/emtricitabine)
Description: Tenofovir/emtricitabine fixed dose combination once daily